Compare Heron Therapeutics Inc (HRTX) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while MONDELEZ INTERNATIONAL INC Common Stock trades at $60.48 (market cap $77.43B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 1138.5× Heron Therapeutics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and MONDELEZ INTERNATIONAL INC Common Stock for 107 Days on average.
| HRTX | MDLZ | |
|---|---|---|
Market Cap | $68.01M | $77.43B |
Volume | 1,891,941 | 7,695,104 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $64.99 |
52-Week Low | $0.27 | $51.51 |
Typical Hold Time | 35 Days | 107 Days |
Enterprise Value | $174.75M | $97.78B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Mondelez International (MDLZ) trades at $60.39, up 1.7% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $0.73 exceeding expectations, supported by $38.54B revenue in 2025. Recent dividend increase to $0.52 per share and positive media coverage highlight management's confidence in cash flow stability. Valuation metrics include P/E of 22.22 and P/S of 1.97, trading below the consensus price target of $70.29.
MDLZ presents a compelling investment case with 76% analyst buy ratings and 16% upside to target, though cocoa cost pressures and margin compression from 13.76% in 2023 to 6.36% in 2025 pose near-term risks. The company's global brand portfolio and emerging market growth provide long-term stability, but investors should monitor commodity inflation's impact on profitability amid current neutral oscillator signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
